Universal Beteiligungs und Servicegesellschaft mbH Purchases 17,799 Shares of Moderna, Inc. (NASDAQ:MRNA)

Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 4.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 452,713 shares of the company's stock after purchasing an additional 17,799 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.12% of Moderna worth $12,834,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Itau Unibanco Holding S.A. boosted its holdings in Moderna by 51.2% during the 4th quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company's stock worth $42,000 after acquiring an additional 343 shares during the last quarter. Deseret Mutual Benefit Administrators increased its position in shares of Moderna by 53.3% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 1,128 shares of the company's stock valued at $32,000 after purchasing an additional 392 shares during the last quarter. Parallel Advisors LLC boosted its stake in Moderna by 11.4% in the first quarter. Parallel Advisors LLC now owns 4,403 shares of the company's stock valued at $125,000 after acquiring an additional 451 shares during the last quarter. Xponance Inc. grew its stake in shares of Moderna by 1.4% during the 1st quarter. Xponance Inc. now owns 45,412 shares of the company's stock worth $1,287,000 after acquiring an additional 642 shares during the period. Finally, Quadrant Capital Group LLC grew its stake in shares of Moderna by 38.2% during the 4th quarter. Quadrant Capital Group LLC now owns 2,520 shares of the company's stock worth $105,000 after acquiring an additional 697 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts have recently weighed in on MRNA shares. JPMorgan Chase & Co. decreased their price target on shares of Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a report on Thursday, May 22nd. Royal Bank Of Canada reduced their target price on shares of Moderna from $32.00 to $28.00 and set a "sector perform" rating on the stock in a report on Friday, May 2nd. Barclays reaffirmed an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Evercore ISI reduced their target price on shares of Moderna from $50.00 to $32.00 and set an "in-line" rating on the stock in a report on Friday, May 2nd. Finally, Wells Fargo & Company reiterated an "equal weight" rating on shares of Moderna in a report on Sunday, July 13th. Four research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, Moderna has an average rating of "Hold" and a consensus price target of $46.11.

Moderna Trading Up 0.4%

Moderna stock traded up $0.14 during mid-day trading on Friday, hitting $34.15. The company had a trading volume of 5,367,762 shares, compared to its average volume of 9,132,097. The stock's 50 day moving average price is $28.58 and its two-hundred day moving average price is $30.68. Moderna, Inc. has a 12 month low of $23.15 and a 12 month high of $125.68. The company has a market capitalization of $13.21 billion, a PE ratio of -3.91 and a beta of 1.84.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($2.52) EPS for the quarter, topping analysts' consensus estimates of ($2.92) by $0.40. The business had revenue of $108.00 million during the quarter, compared to analyst estimates of $130.35 million. Moderna had a negative return on equity of 28.69% and a negative net margin of 105.67%. The company's quarterly revenue was down 35.3% compared to the same quarter last year. During the same quarter last year, the company earned ($3.07) EPS. Equities research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.